Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the ...

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina (ILMN) is capturing attention following the debut of its proprietary 5-base sequencing solution and impressive results from GeneDx’s pilot of the constellation platform. Both developments ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

The Broad Institute gene-sequencing lab used Roche equipment to read infants’ DNA genomes in less than four hours, cutting an hour off the previous Guinness World Record.

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on ...

In June 2025, the US Food and Drug Administration (FDA) issued a final guidance titled Cybersecurity in Medical Devices: ...